A randomised controlled trial evaluating the effects of long-term low-dose corticosteroid therapy compared to placebo on flare rates during maintenance therapy for proliferative lupus nephritis: a pilot study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
18/09/2006		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
12/10/2006	Completed	[X] Results		
Last Edited 28/03/2017	Condition category Musculoskeletal Diseases	Individual participant data		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Braden Manns

Contact details

Division of Nephrology
Foothills Hospital
1403-29th St NW
Calgary
Canada
T2N 2T9
+1 (0)403 944 1110
Braden.Manns@CalgaryHealthRegion.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

18864

Study information

Scientific Title

A randomised controlled trial evaluating the effects of long-term low-dose corticosteroid therapy compared to placebo on flare rates during maintenance therapy for proliferative lupus nephritis: a pilot study

Acronym

SIMPL

Study objectives

Comparison of flare of lupus rates in patients randomised to low-dose corticosteroids to those randomised to corticosteroid discontinuation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

University of Calgary Conjoint Medical Ethics Committee (Canada)

Study design

Blinded randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Systemic lupus erythematosus and lupus nephritis

Interventions

Prednisone/Prednisilone 7.5 mg versus placebo

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Corticosteroids

Primary outcome measure

Time to flare of SLE

Secondary outcome measures

- 1. Time to renal flare
- 2. Differences in quality of life as measured by Short Form 36 and Euroquol 5D instrument
- 3. Differences in disease activity as measured by British Isles Lupus Activity Grade and Systemic Lupus Erythematosus Activity Index
- 4. Differences in disease damage as measured by the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage score
- 5. Differences in steroid-related adverse events

Overall study start date

30/09/2006

Completion date

31/12/2007

Eligibility

Key inclusion criteria

- 1. 18 years of age or older
- 2. American College of Rheumatology defined systemic lupus erythematosus
- 3. International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis on last renal biopsy
- 4. In complete or partial remission
- 5. Currently on corticosteroids
- 6. Informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

30

Key exclusion criteria

- 1. Receiving steroids for a non-Systemic Lupus Erythematosus (SLE) indication
- 2. Currently pregnant
- 3. On a form of renal replacement therapy or having received a renal transplantation

Date of first enrolment

30/09/2006

Date of final enrolment

31/12/2007

Locations

Countries of recruitment

Canada

United Kingdom

Study participating centre Foothills Hospital

Calgary

Canada

T2N 2T9

Sponsor information

Organisation

University of Calgary (Canada)

Sponsor details

3330 Hospital Drive NW Calgary Canada T2N 4N1

Sponsor type

University/education

Website

http://www.ucalgary.ca/

ROR

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Centre for Advancement of Health (Canada)

Funder Name

Division of Nephrology (Canada)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	28/11/2014		Yes	No